Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis

Drugs and Aging

Volumn 26, Issue 4, 2009, Pages 273-293

  Díaz Borjón, Alejandro ^a,b  

^a HOSPITAL ÁNGELES LOMAS   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALLOPURINOL; ANTIMALARIAL AGENT; AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLUENZA VACCINE; LEFLUNOMIDE; MESALAZINE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PNEUMOCOCCUS VACCINE; PYRIDOXINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; AGING; AGRANULOCYTOSIS; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; APLASTIC ANEMIA; ARTHRALGIA; ASTHENIA; B CELL LYMPHOMA; BACKACHE; BONE DEMINERALIZATION; BONE MARROW SUPPRESSION; BRONCHOSPASM; CARDIOMYOPATHY; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORNEA DISEASE; COUGHING; CREATININE CLEARANCE; CRYSTALLURIA; CYTOPENIA; DEMYELINATING DISEASE; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSLIPIDEMIA; DYSPEPSIA; ELECTROLYTE DISTURBANCE; FOLIC ACID DEFICIENCY; GERIATRIC CARE; GOUT; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HEMATURIA; HEMOLYTIC ANEMIA; HEPATITIS B; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERPIGMENTATION; HYPERSENSITIVITY; HYPERTENSION; HYPERURICEMIA; HYPOTENSION; IMMUNIZATION; INFECTION; INFECTION SENSITIVITY; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; KIDNEY CLEARANCE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG INFILTRATE; LUNG NODULE; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEGALOBLASTIC ANEMIA; META ANALYSIS; MONOTHERAPY; MOUTH ULCER; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OTOTOXICITY; PANCYTOPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PYRIDOXINE DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SKIN NODULE; SKIN PIGMENTATION; STOMATITIS; SYNCOPE; SYSTEMATIC REVIEW; TERATOGENESIS; THROMBOCYTOPENIA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERTIGO; VOMITING; AGED; PATHOPHYSIOLOGY;

AGED; AGING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOLOGIC FACTORS; PRACTICE GUIDELINES AS TOPIC;

EID: 67649993328     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-200926040-00001     Document Type: Review

References (185)

1. Sherrer YS, Bloch DA, Mitchell DM, et al. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986 Apr; 29 (4): 494-500
2. Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986 Jun; 29 (6): 706-14
3. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007 Oct; 21 (5): 885-906
4. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999 Mar; 42 (3): 415-20
5. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008 Jan; 58 (1): 15-25
6. Linos A, Worthington JW, O'Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980 Jan; 111 (1): 87-98
7. Terkeltaub R, Esdaile J, Decary F, et al. A clinical study of older age rheumatoid arthritis with comparison to a younger onset group. J Rheumatol 1983 Jun; 10 (3): 418-24
8. van Schaardenburg D, Breedveld FC. Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 1994 Jun; 23 (6): 367-78
9. Deal CL, Meenan RF, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis: a comparison with younger-onset disease of similar duration. Arthritis Rheum 1985 Sep; 28 (9): 987-94
10. Ferraccioli GF, Cavalieri F, Mercadanti M, et al. Clinical features, scintiscan characteristics and X-ray progression of late onset rheumatoid arthritis. Clin Exp Rheumatol 1984 Apr-Jun; 2 (2): 157-61
11. van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective follow-up study of early rheumatoid arthritis. J Rheumatol 1991 Sep; 18 (9): 1285-9
12. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am 2007 Feb; 33 (1): 57-70
13. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002 Feb; 46 (2): 328-46
14. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004 Jun 17; 350 (25): 2591-602
15. Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007 Aug 15; 57 (6): 928-34
16. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology (Oxford) 2006 Dec; 45 (12): 1555-7
17. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006 Sep; 65 (9): 1226-9
18. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007 (1): CD006356
19. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 2002 Aug; 18 (3): 577-92
20. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007 Feb; 33 (1): 197-217
21. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003 Aug; 38 (8): 843-53
22. Percy LA, Fang MA. Geropharmacology for the rheumatologist. Rheum Dis Clin North Am 2000 Aug; 26 (3): 433-54, v-vi
23. Ravikumar R, Anolik J, Looney RJ. Vaccine responses in patients with rheumatoid arthritis. Curr Rheumatol Rep 2007 Oct; 9 (5): 407-15
24. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med 2007 Nov 20; 147 (10): 725-9
25. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 May 30; 59 (6): 762-84
26. Brezinschek HP, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008 May; 20 (3): 295-9
27. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007 May; 34 (5): 952-7
28. Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007 Apr; 46 (4): 608-11
29. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response. Ann Rheum Dis 2008 Jul; 67 (7): 937-41
30. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002 Nov 5; 137 (9): 726-33
31. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996 May 16; 334 (20): 1287-91
32. O'Dell JR. Combination DMARD therapy for rheumatoidarthritis: a step closer to the goal. Ann Rheum Dis 1996 Nov; 55 (11): 781-3
33. O'Dell JR, Haire C, Erikson N, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol Suppl 1996 Mar; 44: 72-4
34. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997 Aug 2; 350 (9074): 309-18
35. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999 May 8; 353 (9164): 1568-73
36. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005 Nov; 52 (11): 3381-90
37. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951 Feb; 221 (2): 176-82
38. Gubner R. Therapeutic suppression of tissue reactivity: I. Comparison of the effects of cortisone and aminopterin. Am J Med Sci 1951 Feb; 221 (2): 169-75
39. Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984 Dec; 11 (6): 760-3
40. Andersen PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985 Oct; 103 (4): 489-96
41. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985 Dec; 12 Suppl. 12: 35-9
42. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985 Mar 28; 312 (13): 818-22
43. Williams HJ, Willkens RF, Samuelson Jr CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985 Jul; 28 (7): 721-30
44. Alarcon GS, Lopez-Mendez A, Walter J, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992 Dec; 19 (12): 1868-73
45. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol 1995 Feb; 22 (2): 218-23
46. Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991 Jul; 18 (7): 973-7
47. Bologna C, Viu P, Jorgensen C, et al. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol 1996 May; 35 (5): 453-7
48. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65 (3): 168-73
49. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997 Nov; 23 (4): 739-55
50. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992 Oct; 16 (5): 411-23
51. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging 2003; 20 (10): 723-36
52. Bressolle F, Bologna C, Kinowski JM, et al. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis: a comparison with young patients. J Rheumatol 1997 Oct; 24 (10): 1903-9
53. Sandoval DM, Alarcon GS, Morgan SL. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995 Nov; 34 Suppl. 2: 49-56
54. Alarcon GS, Tracy IC, Strand GM, et al. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995 Sep; 54 (9): 708-12
55. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992 Oct; 35 (10): 1117-25
56. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989 Jun; 32 (6): 770-5
57. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997 Aug; 24 (8): 1489-94
58. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004 Mar; 43 (3): 267-71
59. Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000951
60. Harten P. Reducing toxicity of methotrexate with folic acid [in German]. Z Rheumatol 2005 Jun; 64 (5): 353-8
61. Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998 Mar; 25 (3): 441-6
62. Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol 1990 Dec; 4 (3): 467-89
63. Adams EM, Yocum DE, Bell CL. Hydroxychloroquine in the treatment of rheumatoid arthritis. Am J Med 1983 Aug; 75 (2): 321-6
64. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993 Dec 1; 119 (11): 1067-71
65. Jessop JD, O'Sullivan MM, Lewis PA, et al. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1998 Sep; 37 (9): 992-1002
66. Davis MJ, Dawes PT, Fowler PD, et al. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991 Dec; 30 (6): 451-4
67. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, et al. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 1998 Oct; 57 (10): 582-7
68. Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol 2000 Feb; 27 (2): 523-9
69. Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med 1983 Jul 18; 75 (1A): 52-6
70. Trnavsky K, Gatterova J, Linduskova M, et al. Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis. Z Rheumatol 1993 Sep-Oct; 52 (5): 292-6
71. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993 Oct; 23 (2 Suppl. 1): 82-91
72. Fox RI, Kang HI. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993 Feb; 2 Suppl. 1: S9-12
73. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996 Jun; 5 Suppl. 1: S11-5
74. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002 Jul; 109 (7): 1377-82
75. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991 Aug; 23 (8): 292-6
76. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983 Jul 18; 75 (1A): 40-5
77. Araiza-Casillas R, Cardenas F, Morales Y, et al. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13 (2): 119-24
78. Ferris 3rd FL. Senile macular degeneration: review of epidemiologic features. Am J Epidemiol 1983 Aug; 118 (2): 132-51
79. Taggart AJ. Sulphasalazine in arthritis: an old drug rediscovered. Clin Rheumatol 1987 Sep; 6 (3): 378-83
80. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988 May; 83 (5): 497-503
81. Sinclair RJG, Duthie JJR. Salazopyrin in the treatment of rheumatoid arthritis. Ann Rheum Dis 1949; 8 (3): 226-31
82. McConkey B, Amos RS, Durham S, et al. Sulphasalazine in rheumatoid arthritis. BMJ 1980 Feb 16; 280 (6212): 442-4
83. Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 1999 Oct; 26 (10): 2123-30
84. Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. J Rheumatol 1992 Nov; 19 (11): 1672-7
85. Hannonen P, Mottonen T, Hakola M, et al. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993 Nov; 36 (11): 1501-9
86. Pincus T, Ferraccioli G, Sokka T, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002 Dec; 41 (12): 1346-56
87. van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989 May 13; 1 (8646): 1036-8
88. Haagsma CJ, van Riel PL, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997 Oct; 36 (10): 1082-8
89. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999 Jan 23; 353 (9149): 259-66
90. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990 Oct; 33 (10): 1449-61
91. Nuver-Zwart IH, van Riel PL, van de Putte LB, et al. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989 May; 48 (5): 389-95
92. Wilkieson CA, Madhok R, Hunter JA, et al. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med 1993 Aug; 86 (8): 501-5
93. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999 Apr; 58 (4): 220-5
94. Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? BMJ (Clin Res Ed) 1985 May 25; 290 (6481): 1535-8
95. Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid: which is the active moiety in rheumatoid arthritis? Br J Rheumatol 1995 Nov; 34 Suppl. 2: 16-9
96. Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998 Jan 15; 101 (2): 295-300
97. Tett SE. Clinical pharmacokinetics of slow-acting anti-rheumatic drugs. Clin Pharmacokinet 1993 Nov; 25 (5): 392-407
98. Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995 Jul; 50: 137-56
99. Pullar T, Hunter JA, Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 1985 Dec; 44 (12): 831-7
100. Kitas GD, Farr M, Waterhouse L, et al. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992; 21 (5): 220-5
101. Taggart AJ, McDermott B, Delargy M, et al. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. Scand J Rheumatol Suppl 1987; 64: 29-36
102. Figlin E, Chetrit A, Shahar A, et al. High prevalences of vitamin B12 and folic acid deficiency in elderly subjects in Israel. Br J Haematol 2003 Nov; 123 (4): 696-701
103. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity: I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985; 7 (1): 7-18
104. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995 Nov; 38 (11): 1595-603
105. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999 Nov 22; 159 (21): 2542-50
106. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun; 39 (6): 655-65
107. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001 Sep; 44 (9): 1984-92
108. Olivieri I, Palazzi C, Peruz G, et al. Management issues with elderly-onset rheumatoid arthritis: an update. Drugs Aging 2005; 22 (10): 809-22
109. Chan J, Sanders DC, Du L, et al. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004 Jul-Aug; 38 (7-8): 1206-11
110. Williams HJ, Ward JR. Comparison of oral and parenteral gold therapy and placebo in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl 1983; 51: 92-9
111. Ward JR, Williams HJ, Boyce E, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: subsets of responses. Am J Med 1983 Dec 30; 75 (6A): 133-7
112. Jones G, Brooks PM. Injectable gold compounds: an overview. Br J Rheumatol 1996 Nov; 35 (11): 1154-8
113. Katz WA, Alexander S, Bland JH, et al. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol Suppl 1982 Jul-Aug; 8: 173-8
114. Tozman EC, Gottlieb NL. Adverse reactions with oral and parenteral gold preparations. Med Toxicol 1987 May-Jun; 2 (3): 177-89
115. Glennas A, Kvien TK, Andrup O, et al. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol 1997 Aug; 36 (8): 870-7
116. Bluhm GB. The mechanisms of action of conventional chrysotherapy. J Rheumatol Suppl 1982 Jul-Aug; 8: 10-7
117. Lorber A, Jackson WH, Simon TM. Effects of chrysotherapy on cell mediated immune response. J Rheumatol Suppl 1982 Jul-Aug; 8: 37-45
118. Nixon J, Pande I. Gold, nitritoid reactions and angiotensinconverting enzyme inhibitors. Rheumatology (Oxford) 2006 Jan; 45 (1): 118-9
119. Munthe E, Kass E. Penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy. J Rheumatol Suppl 1981 Jan-Feb; 7: 107-11
120. Williams HJ, Ward JR, Reading JC, et al. Low-dose D-penicillamine therapy in rheumatoid arthritis: a controlled, double-blind clinical trial. Arthritis Rheum 1983 May; 26 (5): 581-92
121. Lipsky PE, Ziff M. Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4. J Clin Invest 1980 May; 65 (5): 1069-76
122. Jaffe IA. Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963 Mar; 22: 71-6
123. Dahl SL, Samuelson CO, Williams HJ, et al. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 1990; 10 (2): 79-84
124. Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994 May; 37 (5): 629-36
125. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995 Jan 15; 122 (2): 81-9
126. O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997 May; 40 (5): 842-8
127. O'Dell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999 Aug; 42 (8): 1691-5
128. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001 Oct; 44 (10): 2235-41
129. Bluhm GB, Sharp JT, Tilley BC, et al. Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. J Rheumatol 1997 Jul; 24 (7): 1295-302
130. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996 Nov 26; 93 (24): 14014-9
131. Alarcon GS. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2000 Jul; 9 (7): 1491-8
132. Fanning WL, Gump DW. Distressing side-effects of minocycline hydrochloride. Arch Intern Med 1976 Jul; 136 (7): 761-2
133. Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003 Jan; 42 (1): 6-13
134. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996 Jun; 39 (6): 1006-15
135. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995 Jul 20; 333 (3): 137-41
136. Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999 Sep; 15 (3): 197-205
137. Gremese E, Ferraccioli GF. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol 2004 Sep-Oct; 22 (5 Suppl. 35): S101-7
138. Urowitz MB, Gordon DA, Smythe HA, et al. Azathioprine in rheumatoid arthritis: a double-blind, cross over study. Arthritis Rheum 1973 May-Jun; 16 (3): 411-8
139. Gordon DA, Urowitz MB. Use of azathioprine for rheumatoid arthritis. Arthritis Rheum 1982 Oct; 25 (10): 1269-70
140. van Wanghe P, Dequeker J. Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases. Ann Rheum Dis 1982; 41 Suppl. 1: 40-3
141. Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000 (4): CD001461
142. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991 Aug; 34 (8): 961-72
143. Sambrook PN, Champion GD, Browne CD, et al. Comparison of methotrexate with azathioprine or 6-mercaptopurine in refractory rheumatoid arthritis: a life-table analysis. Br J Rheumatol 1986 Nov; 25 (4): 372-5
144. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991 Nov; 151 (11): 2249-54
145. Elion GB. The George Hitchings and Gertrude Elion Lecture: the pharmacology of azathioprine. Ann N Y Acad Sci 1993; 685: 400-7
146. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996 Sep; 30 (9): 951-4
147. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005 May; 45: 490-7
148. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46 (8): 645-60
149. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003 Jun; 25 (6): 1700-21
150. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337 (3): 141-7
151. Moreland LW, Schiff MH, Baumgartner SW, et al. Etaercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999 Mar 16; 130 (6): 478-86
152. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344 (8930): 1105-10
153. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 May; 63 (5): 508-16
154. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002; 4 Suppl. 2: S22-8
155. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004 Feb 28; 363 (9410): 675-81
156. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006 Jan; 54 (1): 26-37
157. Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006 Feb; 33 (2): 234-43
158. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003 Apr; 30 (4): 691-6
159. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006 Mar; 65 (3): 379-84
160. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005 May; 44 (5): 695-6
161. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007 Jun; 56 (6): 1754-64
162. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998 Dec; 41 (12): 2196-04
163. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 Mar; 46 (3): 614-24
164. Kineret® (anakinra) [summary of product characteristics]. Stockholm: Biovitrum AB (publ), 2003
165. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2004 May; 30 (2): 237-55, v
166. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004 May; 50 (5): 1412-9
167. Weyand CM, Goronzy JJ, Takemura S, et al. Cell-cell interactions in synovitis: interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res 2000; 2 (6): 457-63
168. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-96
169. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003 Jun; 48 (6): 1484-92
170. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 Jun 17; 350 (25): 2572-81
171. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54 (9): 2793-806
172. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 Jan 15; 83 (2): 435-45
173. Mathas S, Rickers A, Bommert K, et al. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000 Dec 15; 60 (24): 7170-6
174. Wood AM. Rituximab: an innovative therapy for non-Hodgkin's lymphoma. Am J Health Syst Pharm 2001 Feb 1; 58 (3): 215-29
175. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005 Jun 20; 23 (18): 4117-26
176. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007 Nov; 66 Suppl. 3: iii2-22
177. Soriano ER, Galarza-Maldonado C, Cardiel MH, et al. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology (Oxford) 2008 Jul; 47 (7): 1097-9
178. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212
179. Dumont FJ. Technology evaluation: abatacept, BristolMyers Squibb. Curr Opin Mol Ther 2004 Jun; 6 (3): 318-30
180. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996 Oct 31; 335 (18): 1369-77
181. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 Nov 13; 349 (20): 1907-15
182. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002 Jun; 46 (6): 1470-9
183. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 Sep 15; 353 (11): 1114-23
184. Orencia® (abatacept) [product information]. Princeton (NJ): Bristol-Myers Squibb Company, 2008 Apr
185. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007 Feb; 66 (2): 228-34